JP2005523270A - 体重を減少させる方法としてのｃｐｔ−１の促進 - Google Patents

体重を減少させる方法としてのｃｐｔ−１の促進 Download PDF

Info

Publication number
JP2005523270A
JP2005523270A JP2003565467A JP2003565467A JP2005523270A JP 2005523270 A JP2005523270 A JP 2005523270A JP 2003565467 A JP2003565467 A JP 2003565467A JP 2003565467 A JP2003565467 A JP 2003565467A JP 2005523270 A JP2005523270 A JP 2005523270A
Authority
JP
Japan
Prior art keywords
cpt
activity
fatty acid
malonyl
coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523270A5 (https=
Inventor
スパリ，ジャガン・エヌ
ランドリー，レスリー・イー
ロネット，ガブリエル
クハジュダ，フランシス・ピー
Original Assignee
ジョーンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジョーンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン filed Critical ジョーンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン
Publication of JP2005523270A publication Critical patent/JP2005523270A/ja
Publication of JP2005523270A5 publication Critical patent/JP2005523270A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pediatric Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2003565467A 2002-02-08 2003-02-10 体重を減少させる方法としてのｃｐｔ−１の促進 Pending JP2005523270A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35448002P 2002-02-08 2002-02-08
PCT/US2003/003839 WO2003066043A1 (en) 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009241309A Division JP2010047594A (ja) 2002-02-08 2009-10-20 体重を減少させる方法としてのｃｐｔ−１の促進

Publications (2)

Publication Number Publication Date
JP2005523270A true JP2005523270A (ja) 2005-08-04
JP2005523270A5 JP2005523270A5 (https=) 2006-03-30

Family

ID=27734382

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003565467A Pending JP2005523270A (ja) 2002-02-08 2003-02-10 体重を減少させる方法としてのｃｐｔ−１の促進
JP2009241309A Pending JP2010047594A (ja) 2002-02-08 2009-10-20 体重を減少させる方法としてのｃｐｔ−１の促進

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009241309A Pending JP2010047594A (ja) 2002-02-08 2009-10-20 体重を減少させる方法としてのｃｐｔ−１の促進

Country Status (12)

Country Link
US (4) US20050143467A1 (https=)
EP (1) EP1471906A4 (https=)
JP (2) JP2005523270A (https=)
KR (1) KR20040082417A (https=)
CN (1) CN1313089C (https=)
AU (2) AU2003215111A1 (https=)
BR (1) BR0307421A (https=)
CA (1) CA2474884A1 (https=)
EA (1) EA007029B1 (https=)
IL (1) IL163312A (https=)
MX (1) MXPA04007556A (https=)
WO (1) WO2003066043A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500363A (ja) * 2004-05-26 2008-01-10 ファスジェン・リミテッド・ライアビリティ・カンパニー 新規化合物、該化合物を含む医薬組成物、および該化合物の使用方法
JP2008545770A (ja) * 2005-06-06 2008-12-18 エフ．ホフマン−ラ ロシュ アーゲー 肝臓のカルニチンパルミトイルトランスフェラーゼ（ｌ−ｃｐｔ１）阻害剤として有用なスルホンアミド誘導体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
EP2386551A1 (en) * 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20080119548A1 (en) * 2004-03-18 2008-05-22 Ronnett Gabrielle V Control Of Feeding Behavior By Changing Neuronal Energy Balance
WO2007014248A2 (en) * 2005-07-26 2007-02-01 Johns Hopkins University Method of reducing food intake
ATE418603T1 (de) * 2005-08-29 2009-01-15 Hoffmann La Roche Kristallstrukturen von carnitine palmitoyltransferase-2 (cpt-2) und deren verwendung
ES2405259B1 (es) * 2011-11-25 2014-09-29 Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574639A (en) 1897-01-05 Gold-saving device
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
AU784495B2 (en) * 1999-11-12 2006-04-13 Johns Hopkins University School Of Medicine, The Treating cancer by increasing intracellular malonyl coa levels
KR20030016228A (ko) * 2000-02-16 2003-02-26 존스 홉킨스 유니버시티 스쿨 오브 메디슨 신경펩티드 ｙ 농도의 감소에 의해 유도되는 체중 감량
WO2002079501A1 (en) * 2001-03-30 2002-10-10 Trustees Of Boston University Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
US20040161803A1 (en) * 2002-04-01 2004-08-19 Corkey Barbara E. Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
EP1534263A4 (en) 2002-07-01 2006-10-11 Fasgen Llc NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF ADMINISTRATION THEREFOR
EP2386551A1 (en) 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500363A (ja) * 2004-05-26 2008-01-10 ファスジェン・リミテッド・ライアビリティ・カンパニー 新規化合物、該化合物を含む医薬組成物、および該化合物の使用方法
JP2008545770A (ja) * 2005-06-06 2008-12-18 エフ．ホフマン−ラ ロシュ アーゲー 肝臓のカルニチンパルミトイルトランスフェラーゼ（ｌ−ｃｐｔ１）阻害剤として有用なスルホンアミド誘導体
JP4880678B2 (ja) * 2005-06-06 2012-02-22 エフ．ホフマン−ラ ロシュ アーゲー 肝臓のカルニチンパルミトイルトランスフェラーゼ（ｌ−ｃｐｔ１）阻害剤として有用なスルホンアミド誘導体

Also Published As

Publication number Publication date
CA2474884A1 (en) 2003-08-14
AU2003215111A1 (en) 2003-09-02
US20050143467A1 (en) 2005-06-30
CN1638758A (zh) 2005-07-13
KR20040082417A (ko) 2004-09-24
WO2003066043A1 (en) 2003-08-14
BR0307421A (pt) 2004-12-28
IL163312A (en) 2011-12-29
US7459481B2 (en) 2008-12-02
EP1471906A1 (en) 2004-11-03
JP2010047594A (ja) 2010-03-04
US20090124684A1 (en) 2009-05-14
AU2008249144A1 (en) 2008-12-11
MXPA04007556A (es) 2005-12-05
CN1313089C (zh) 2007-05-02
EP1471906A4 (en) 2006-02-01
US20070087037A1 (en) 2007-04-19
US20050106217A1 (en) 2005-05-19
EA200401052A1 (ru) 2005-02-24
EA007029B1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
JP2010047594A (ja) 体重を減少させる方法としてのｃｐｔ−１の促進
Ma et al. BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16
Chen et al. O-GlcNAcylated c-Jun antagonizes ferroptosis via inhibiting GSH synthesis in liver cancer
Huddleson et al. Induction of KLF2 by fluid shear stress requires a novel promoter element activated by a phosphatidylinositol 3-kinase-dependent chromatin-remodeling pathway
Choi et al. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPα and STAT-3
Ishizuka et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-κB activation and the production of inflammatory cytokines in human endothelial cells
Kwon et al. Patulin induces colorectal cancer cells apoptosis through EGR-1 dependent ATF3 up-regulation
Chun et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1α isoform: implications for tumor promotion
Garg et al. Mechanisms of nitrosothiol-induced antimitogenesis in aortic smooth muscle cells
Guo et al. SF-deferoxamine, a bone-seeking angiogenic drug, prevents bone loss in estrogen-deficient mice
Guerra et al. Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells
JP5539653B2 (ja) 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法
Fiebich et al. The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alphal-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IκB-alpha
Chen et al. Stimulation of inducible nitric oxide synthase by monosodium urate crystals in macrophages and expression of iNOS in gouty arthritis
Oguri et al. Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism
Gadano et al. Vascular nitric oxide production during the development of two experimental models of portal hypertension
Li et al. Upregulation of mitochondrial telomerase reverse transcriptase mediates the preventive effect of physical exercise on pathological cardiac hypertrophy via improving mitochondrial function and inhibiting oxidative stress
US9364480B2 (en) Pharmaceutical composition for preventing or treating cancer, containing enoblock as active ingredient
Zhou et al. Regulation of hypoxia-inducible factor 1 by glucose availability under hypoxic conditions
Ogura et al. Transport Mechanisms for the Nutritional Supplement β-Hydroxy-β-Methylbutyrate (HMB) in Mammalian Cells: Ogura et al.
Schmidt et al. Exogenous nitric oxide regulates activity and synthesis of vascular endothelial nitric oxide synthase
GB2392386A (en) Medical use of perfluoro compounds
Walaszek et al. Repression by sustained‐release β‐glucuronidase inhibitors of chemical carcinogen‐mediated induction of a marker oncofetal protein in rodents
Anfossi et al. Glyceryl trinitrate enhances the adenosine‐induced inhibition of platelet responses: A mechanism potentially involved in the in vivo anti‐aggregating effects of organic nitrates
Heinroth‐Hoffmann et al. Influence of trapidil and trapidil derivatives on the content of cyclic nucleotides in human intima cells cultured from atherosclerotic plaques

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091228